Patents by Inventor D. Scott Edwards

D. Scott Edwards has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FLUORINATED INTEGRIN ANTAGONISTS
    Publication number: 20240140942
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: June 21, 2023
    Publication date: May 2, 2024
    Inventors: Ben C. ASKEW, Richard W. HEIDEBRECHT, Takeru FURUYA, Mark E. DUGGAN, D. Scott EDWARDS
  • Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives
    Patent number: 11858900
    Abstract: The application relates to 2-amino-4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: January 2, 2024
    Assignee: OcuTerra Therapeutics, Inc.
    Inventors: D. Scott Edwards, Ben C. Askew, Takeru Furuya
  • Fluorinated integrin antagonists
    Patent number: 11685737
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: June 27, 2023
    Assignee: OcuTerra Therapeutics, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED AlphaV INTEGRIN ANTAGONISTS
    Publication number: 20230129394
    Abstract: The present application relates to use of fluorinated compounds of Formula (I) in treating or preventing a viral infection or a condition or symptom associated with the viral infection.
    Type: Application
    Filed: November 8, 2022
    Publication date: April 27, 2023
    Inventor: D. Scott Edwards
  • FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES
    Publication number: 20210309612
    Abstract: The application relates to 2-amino-4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.
    Type: Application
    Filed: January 11, 2021
    Publication date: October 7, 2021
    Inventors: D. Scott EDWARDS, Ben C. ASKEW, Takeru FURUYA
  • FLUORINATED INTEGRIN ANTAGONISTS
    Publication number: 20210163473
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: August 12, 2020
    Publication date: June 3, 2021
    Inventors: Ben C. ASKEW, Richard W. HEIDEBRECHT, Takeru FURUYA, Mark E. DUGGAN, D. Scott EDWARDS
  • Fluorinated 4-(substituted amino)phenyl carbamate derivatives
    Patent number: 10676437
    Abstract: The application relates to 4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: June 9, 2020
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Takeru Furuya, Ben C. Askew, D. Scott Edwards
  • FLUORINATED INTEGRIN ANTAGONISTS
    Publication number: 20190263810
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Inventors: Ben C. ASKEW, Richard HEIDEBRECHT, Takeru FURUYA, Mark E. DUGGAN, D. Scott EDWARDS
  • FLUORINATED 4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES
    Publication number: 20190177274
    Abstract: The application relates to 4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 13, 2019
    Inventors: Takeru FURUYA, Ben C. ASKEW, D. Scott EDWARDS
  • Fluorinated integrin antagonists
    Patent number: 10106537
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: October 23, 2018
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • Fluorinated benzofuran derivatives
    Patent number: 9895340
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 20, 2018
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
  • FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES
    Publication number: 20170355679
    Abstract: The application relates to 2-amino-4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.
    Type: Application
    Filed: June 9, 2017
    Publication date: December 14, 2017
    Inventors: D. Scott EDWARDS, Ben C. ASKEW, Takeru FURUYA
  • FLUORINATED INTEGRIN ANTAGONISTS
    Publication number: 20170291900
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 12, 2017
    Inventors: Ben C. ASKEW, Richard W. HEIDEBRECHT, Takeru FURUYA, Mark E. DUGGAN, D. Scott EDWARDS
  • Fluorinated integrin antagonists
    Patent number: 9717729
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 1, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • FLUORINATED BENZOFURAN DERIVATIVES
    Publication number: 20170189370
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Application
    Filed: March 10, 2017
    Publication date: July 6, 2017
    Inventors: Mark E. DUGGAN, Takeru FURUYA, D. Scott EDWARDS
  • Fluorinated benzofuran derivatives
    Patent number: 9624189
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 18, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
  • FLUORINATED 2-AMINO-4-(BENZYLAMINO)PHENYLCARBAMATE DERIVATIVES
    Publication number: 20170096390
    Abstract: The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Application
    Filed: December 15, 2016
    Publication date: April 6, 2017
    Inventors: Mark E. DUGGAN, Takeru FURUYA, D. Scott EDWARDS, Ajay PUROHIT
  • FLUORINATED INTEGRIN ANTAGONISTS
    Publication number: 20170071939
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: November 4, 2016
    Publication date: March 16, 2017
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
    Patent number: 9572801
    Abstract: The present application relates to use of compounds of formula I for treating or preventing a fibrosis.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: February 21, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, D. Scott Edwards
  • Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
    Patent number: 9556114
    Abstract: The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: January 31, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards, Ajay Purohit